Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine and Poly-ICLC with Bevacizumab for Recurrent Glioblastoma
NCT02754362Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Nov 2016
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 2, open-label trial in glioblastoma (GBM) and glioma, sponsored by NYU Langone Health. Planned start Nov 2016; status: withdrawn.
02
Conditions
glioblastoma (GBM)glioma
Beyond the preview
Go deeper on NCT02754362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754362.